Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 110
- Registration Number
- NCT00468169
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Johnny Kao
- Target Recruit Count
- 33
- Registration Number
- NCT00462735
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 50
- Registration Number
- NCT00402480
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 37
- Registration Number
- NCT00387933
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
HSCT for High Risk Inherited Inborn Errors
- Conditions
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 38
- Registration Number
- NCT00383448
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 21
- Registration Number
- NCT00354913
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2019-08-06
- Target Recruit Count
- 6
- Registration Number
- NCT00350844
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
- Conditions
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 9
- Registration Number
- NCT00344981
- Locations
- 🇺🇸
University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 26
- Registration Number
- NCT00336362
- Locations
- 🇬🇷
George Papanicolaou Hospital, Thessaloniki, Greece
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 150
- Registration Number
- NCT00202644
- Locations
- 🇭🇺
Petz Aladar County Teaching Hospital, Gyor, Hungary
🇵🇹Hospitals da Universidade de Coimbra, Coimbra, Portugal
🇫🇷Hopital Saint Louis - Centre d'Investigation Clinique, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.